Revenue Growth QoQ: Erasca (ERAS)

Graphic logo of erasca.com (ERAS)

Erasca, Inc. (ERAS) brings together leading oncologists to achieve the complete eradication of malignant tumors. The business focuses on developing RAS/MAPK pathway inhibitors for precision therapy, while biomaterial delivery is ensured via strict climate control. The quarterly revenue growth index reflects current sales dynamics, while 0.00 marks a new level, allowing investors to filter out inflationary noise from the company's actual expansion.

ERAS (Erasca Inc) Quarterly Sales Growth history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Erasca (ERAS)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Fundamental company analysis:ERAS - Erasca
Flagship merchandise of erasca.com

Institutional capital evaluates Erasca, Inc. (ERAS) through the lens of commercial scalability. The quarterly sales dynamics capture the percentage shift in revenue relative to the previous period, revealing hidden liquidity trends. For a biotech company, this indicator serves as a marker for the efficiency of monetizing R&D results in oncology. Steady growth in this metric confirms the resilience of the business model, supported by sufficient capital reserves to navigate clinical phases.

Direct competitors

BeiGene Oncology - Quarterly Revenue Growth|HALO: Revenue Growth QoQ|Revolution Medicines Corp (RVMD) - Revenue Growth QoQ|Quarterly Revenue Growth Rate Ascentage Pharma Group International (AAPG)|Revenue Growth QoQ CG Oncology, Inc.|Quarterly Revenue Growth Rate UroGen Pharma Corp URGN|Quarterly Revenue Growth BCAX|Personalis, Inc. - Sales Growth QoQ|Quarterly Revenue Growth DCTH (Delcath Systems)|Quarterly Revenue Increase YMAB|AURA - Revenue Growth QoQ|candeltx.com - Sales Change QoQ|ARAY: Quarterly Revenue Growth|Revenue Dynamics QoQ SLS (SELLAS Life Sciences Group, Inc.)|ACTU (Actuate Therapeutics) - Quarterly Revenue Growth|Quarterly Sales Growth Citius Oncology Inc. (CTOR)|Revenue Growth QoQ TuHURA (HURA)|TARA - Quarterly Revenue Growth Rate|Quarterly Revenue Growth FATE (Fate Therapeutics Inc)|Aadi Bioscience Inc (WHWK) - Quarterly Revenue Growth Rate|TScan - Quarterly Revenue Growth|Champions Oncology, Inc. (CSBR) - Quarterly Sales Growth|XBIT (XBiotech Inc.) - Quarterly Sales Growth|CEL-SCI Corporation (CVM) - Quarterly Revenue Growth|Revenue Growth QoQ OS Therapies|RADX: Quarterly Revenue Increase|Revenue Growth QoQ artivabio.com (ARTV)|Quarterly Sales Growth Rate Adlai Nortye|Quarterly Revenue Growth VERU (Veru Corporation)|Sales Change QoQ TPST (Tempest Tx)|XLO: Quarterly Sales Growth|renovarobio.com (RENB) - Quarterly Sales Growth|Mural Bio (MURA) - Revenue Growth QoQ|Kairos Pharma Inc (KAPA) - Quarterly Revenue Growth|Quarterly Sales Growth OKUR|CytoMed Therapeutics (GDTC) - Quarterly Sales Growth Rate|Quarterly Sales Growth CRIS (Curis Inc.)|Quarterly Revenue Growth Apollomics Inc. (APLM)|Revenue Growth QoQ Tharimmune Corp THAR|Advanced Biomed Corp - Revenue Growth QoQ|GNPX: Quarterly Sales Growth|Calidi Biotherapeutics, Inc. (CLDI) - Quarterly Sales Growth|SBFM: Quarterly Revenue Growth|Quarterly Sales Growth Xenetic Biosciences Inc.|Revenue Growth QoQ Salarius Pharmaceuticals Inc|PPBT: Quarterly Revenue Increase|Quarterly Revenue Growth AONC|BGNE (BeOne Medicines) - Quarterly Revenue Increase|Checkpoint Therapeutics, Inc - Quarterly Sales Growth|elevationoncology.com (ELEV) - Quarterly Revenue Growth Rate|iCAD Inc. - Quarterly Revenue Growth|Quarterly Revenue Growth Rate Ikena Oncology|NTBL: Quarterly Revenue Growth|Quarterly Revenue Growth Rate Viracta (VIRX)|MOR (MorphoSys AG) - Quarterly Revenue Growth|NAYA: Quarterly Revenue Increase|Revenue Growth QoQ Ascentage Pharma Group Ltd (AAPGV)